10.07.2015 Views

BNF for Children 2011-2012

BNF for Children 2011-2012

BNF for Children 2011-2012

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

302 5.2.1 Triazole antifungals <strong>BNF</strong>C <strong>2011</strong>–<strong>2012</strong>5 InfectionsPregnancy manufacturer advises avoid—multiplecongenital abnormalities reported with long-termhigh dosesBreast-feeding present in milk but amount probablytoo small to be harmfulSide-effects nausea, abdominal discom<strong>for</strong>t, diarrhoea,flatulence, headache, rash (discontinue treatmentor monitor closely if infection invasive or systemic);less frequently dyspepsia, vomiting, tastedisturbance, hepatic disorders, angioedema, anaphylaxis,dizziness, seizures, alopecia, pruritus, toxic epidermalnecrolysis, Stevens-Johnson syndrome(severe cutaneous reactions more likely in AIDSpatients), hyperlipidaemia, leucopenia, thrombocytopenia,and hypokalaemia reportedLicensed use not licensed <strong>for</strong> tinea infections inchildren, or <strong>for</strong> vaginal candidiasis in girls under 16years, or <strong>for</strong> prevention of relapse of cryptococcalmeningitis after completion of primary therapy inchildren with AIDSIndication and doseMucosal candidiasis (except genital). By mouth or by intravenous infusionNeonate under 2 weeks 3–6 mg/kg on first daythen 3 mg/kg every 72 hoursNeonate 2–4 weeks 3–6 mg/kg on first day then3 mg/kg every 48 hoursChild 1 month–12 years 3–6 mg/kg on first daythen 3 mg/kg (max. 100 mg) daily <strong>for</strong> 7–14 days inoropharyngeal candidiasis (max. 14 days except inseverely immunocompromised patients); <strong>for</strong> 14–30days in other mucosal infections (e.g. oesophagitis,candiduria, non-invasive bronchopulmonaryinfections)Child 12–18 years 50 mg daily (100 mg daily inunusually difficult infections) given <strong>for</strong> 7–14 daysin oropharyngeal candidiasis (max. 14 days exceptin severely immunocompromised patients); <strong>for</strong> 14–30 days in other mucosal infections (e.g. oesophagitis,candiduria, non-invasive bronchopulmonaryinfections)Vaginal candidiasis (see also Recurrent VulvovaginalCandidiasis, section 7.2.2). By mouthChild under 16 years (post-puberty) a singledose of 150 mgChild 16–18 years a single dose of 150 mgCandidal balanitis. By mouthChild 16–18 years a single dose of 150 mgTinea pedis, corporis, cruris, pityriasis versicolor,and dermal candidiasis. By mouthChild 1 month–18 years 3 mg/kg (max. 50 mg)daily <strong>for</strong> 2–4 weeks (<strong>for</strong> up to 6 weeks in tineapedis); max. duration of treatment 6 weeksTinea capitis. By mouthChild 1–18 years 6 mg/kg (max. 300 mg) daily <strong>for</strong>2–4 weeksInvasive candidal infections (including candidaemiaand disseminated candidiasis) andcryptococcal infections (including meningitis). By mouth or by intravenous infusionNeonate under 2 weeks 6–12 mg/kg every 72hours, treatment continued according to response(at least 8 weeks <strong>for</strong> cryptococcal meningitis)Neonate 2–4 weeks 6–12 mg/kg every 48 hours,treatment continued according to response (atleast 8 weeks <strong>for</strong> cryptococcal meningitis)Child 1 month–18 years 6–12 mg/kg (max.800 mg) daily, treatment continued according toresponse (at least 8 weeks <strong>for</strong> cryptococcalmeningitis)Prevention of relapse of cryptococcal meningitisin HIV-infected patients after completion ofprimary therapy. By mouth or by intravenous infusionChild 1 month–18 years 6 mg/kg (max. 200 mg)dailyPrevention of fungal infections in immunocompromisedpatients. By mouth or by intravenous infusionNeonate under 2 weeks according to extent andduration of neutropenia, 3–12 mg/kg every 72hoursNeonate 2–4 weeks according to extent andduration of neutropenia, 3–12 mg/kg every 48hoursChild 1 month–18 years according to extent andduration of neutropenia, 3–12 mg/kg (max.400 mg) daily; 12 mg/kg (max. 400 mg) daily ifhigh risk of systemic infections e.g. following bonemarrowtransplantation; commence treatmentbe<strong>for</strong>e anticipated onset of neutropenia and continue<strong>for</strong> 7 days after neutrophil count in desirablerangeAdministration <strong>for</strong> intravenous infusion, give over10–30 minutes; do not exceed an infusion rate of 5–10 mL/minuteFluconazole (Non-proprietary) A1Capsules, fluconazole 50 mg, net price 7-cap pack =£1.14; 150 mg, single-capsule pack = 98p; 200 mg, 7-cap pack = £5.04. Label: 9, (50 and 200 mg)Dental prescribing on NHS Fluconazole Capsules 50 mgmay be prescribedIntravenous infusion, fluconazole 2 mg/mL, netprice 25-mL bottle = £7.31; 100-mL bottle = £29.27;100-mL infusion bag = £3.89; 50-mL infusion bag =£2.70Diflucan c (Pfizer) A1Capsules, fluconazole 50 mg (blue/white), net price7-cap pack = £16.61; 150 mg (blue), single-capsulepack = £7.12; 200 mg (purple/white), 7-cap pack =£66.42. Label: 9, (50 and 200 mg)Oral suspension, orange-flavoured, fluconazole <strong>for</strong>reconstitution with water, 50 mg/5 mL, net price1. Capsules can be sold to the public <strong>for</strong> vaginal candidiasisand associated candidal balanitis in those aged 16–18years, in a container or packaging containing not morethan 150 mg and labelled to show a max. dose of 150 mg

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!